What is Myopia & Presbyopia Eye Drops: Overview
Allergan created VUITY, which it claims is the first and only FDA-approved eye drop for the treatment of presbyopia. Allergan, an AbbVie company, announced FDA approval of pilocarpine HCl ophthalmic solution 1.25 percent (VUITY) for the treatment of presbyopia in adults, also known as age-related blurry near vision.Presbyopia, also known as age-related long-sightedness or far-sightedness, is a natural part of the ageing process. It can happen even if you already have myopia because presbyopia is caused by a loss of flexibility in the crystalline lens of the eye, whereas myopia is caused by the shape of your eye.
Myopia, also known as nearsightedness, is a common eye disorder in which a person can see objects farther away blurred but not nearby objects. This is caused by a change in the shape of the eye lens, which causes light rays to bend (refract) incorrectly, causing images to focus in front of the retina rather than on the retina. Furthermore, presbyopia is a condition characterised by a gradual loss of the eyes' ability to focus on nearby objects. It is a natural occurrence that occurs as a result of ageing. Presbyopia is typically diagnosed in the mid-40s, and the condition worsens with age.
The presence of other available treatments for myopia is expected to be a major impediment to the growth of the global Myopia & Presbyopia Eye Drops market. Modified spectacle prescription, orthokeratology (ortho-k), and bifocal/multifocal soft contact lenses are some other options for treating myopia. Increasing cases of vision loss, primarily due to myopia, as well as an increase in the incidence of distance vision impairment due to uncorrected myopia, are expected to drive growth.
Presbyopia's high prevalence is expected to drive market growth. Presbyopia affects more than 1.1 billion people worldwide, with one-third of those affected being over the age of 50. More than 90% of the patients in this pool are from developing countries. As a result, during the forecast period, developing countries are expected to have a high demand for myopia and presbyopia treatment.
Comments
Post a Comment